Advanced search
Publication Cover
Journal of Chemotherapy Volume 36, 2024 - Issue 2
Submit an article Journal homepage
71
Views
0
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Papers

Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases

Atsushi Suzukia Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan;b Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8087-1804View further author information
ORCID Icon,
Kensuke Fukumitsub Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;c Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, JapanView further author information
,
Jun Fukiharab Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;d Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, JapanView further author information
,
Takuma Katanob Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;e Department of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, JapanView further author information
,
Hisashi Kakob Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;f Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, JapanView further author information
,
Yuri Maedab Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;f Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, JapanView further author information
,
Makoto Ishiia Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, JapanView further author information
,
Akio Niimic Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, JapanView further author information
,
Kazuyoshi Imaizumif Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, JapanView further author information
&
Etsuro Yamaguchib Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;e Department of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, JapanView further author information
 show all
Pages 127-132 | Received 27 Dec 2022, Accepted 27 Nov 2023, Published online: 03 Dec 2023

References

  • Clinical Practice Guidance Review Committee. Guidance for medical treatment for COVID-19. 2022. Available form: https://www/mhlw.go.jp/content/000936655.pdf
  • COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health; 2022. Available from: https://www.covid19treatmentguidelines.nih.gov/
  • Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - Final report. N Engl J Med. 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764.
  • Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi: 10.1001/jama.2020.16349.
  • Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315. doi: 10.1056/NEJMoa2116846.
  • Koh LP, Chua SL, Vasoo S, et al. Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: a propensity score adjusted retrospective cohort study. J Med Virol. 2023;95(2):e28460.
  • Pitts J, Li J, Perry JK, et al. Remdesivir and GS-441524 retain antiviral activity against Delta, omicron, and other emergent SARS-CoV-2 variants. Antimicrob Agents Chemother. 2022;66(6):e0022222. doi: 10.1128/aac.00222-22.
  • Mengato D, Mazzitelli M, Francavilla A, et al. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study. Clin Exp Med. 2023;23(6):2749–2756. doi: 10.1007/s10238-023-01036-x.
  • Mazzitelli M, Trunfio M, Sasset L, et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and omicron era: a real-life cohort study. J Med Virol. 2023;95(3):e28660.
  • Horby P, Lim WS, RECOVERY Collaborative Group., et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
  • Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. 2022;28(9):1933–1943. doi: 10.1038/s41591-022-01887-z.
  • Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603(7902):687–692. doi: 10.1038/s41586-022-04441-6.
  • Terada M, Ohtsu H, Saito S, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11(6):e047007. doi: 10.1136/bmjopen-2020-047007.
  • Christensen DM, Strange JE, Gislason G, et al. Charlson comorbidity index score and risk of severe outcome and death in danish COVID-19 patients. J Gen Intern Med. 2020;35(9):2801–2803. doi: 10.1007/s11606-020-05991-z.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.